0001127602-19-021658.txt : 20190614
0001127602-19-021658.hdr.sgml : 20190614
20190614165121
ACCESSION NUMBER: 0001127602-19-021658
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20190612
FILED AS OF DATE: 20190614
DATE AS OF CHANGE: 20190614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HAKAMI HOOMAN
CENTRAL INDEX KEY: 0001610035
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36820
FILM NUMBER: 19899481
MAIL ADDRESS:
STREET 1: 710 MEDTRONIC PKWY
STREET 2: MSLC300
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55432
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Medtronic plc
CENTRAL INDEX KEY: 0001613103
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 000000000
FISCAL YEAR END: 0426
BUSINESS ADDRESS:
STREET 1: 20 ON HATCH, LOWER HATCH STREET
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: 01135314381700
MAIL ADDRESS:
STREET 1: 20 ON HATCH, LOWER HATCH STREET
CITY: DUBLIN
STATE: L2
ZIP: 2
FORMER COMPANY:
FORMER CONFORMED NAME: Medtronic Ltd
DATE OF NAME CHANGE: 20150112
FORMER COMPANY:
FORMER CONFORMED NAME: Medtronic Holdings Ltd
DATE OF NAME CHANGE: 20140711
FORMER COMPANY:
FORMER CONFORMED NAME: Kalani I Ltd
DATE OF NAME CHANGE: 20140709
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2019-06-12
0001613103
Medtronic plc
MDT
0001610035
HAKAMI HOOMAN
710 MEDTRONIC PKWY MS LC300
MINNEAPOLIS
MN
55432
1
EVP & Group President Diabetes
Ordinary Shares
2019-06-12
4
M
0
31731
78.00
A
95337
D
Ordinary Shares
2019-06-12
4
S
0
31731
97.49
D
63606
D
Ordinary Shares
2019-06-12
4
S
0
20933
97.49
D
42673
D
Stock Option (Right to Buy)
78.00
2019-06-12
4
M
0
31731
0
D
2016-08-03
2025-08-03
Ordinary Shares
31731
10578
D
The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.22 to $97.96, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.23 to $97.95, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This balance increased by 959 shares due to exempt transactions such as dividend reinvestment and Employee Stock Purchase Plan.
These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant.
/s/ Perry F. Sekus, attorney-in-fact
2019-06-14
EX-24
2
doc1.txt
POWER OF ATTORNEY (PUBLIC): POA HAKAMI
POWER OF ATTORNEY
Know all by these presents, that the undersigned, director or officer, or both,
of Medtronic plc, hereby constitutes and appoints each of Bradley E. Lerman,
Martha Ha, Thomas L. Osteraas, Perry F. Sekus and Anne M. Ziebell signing
singly, the undersigned?s true and lawful attorney-in-fact to:
(1) prepare, execute in the undersigned?s and on the undersigned?s behalf,
and submit to the U.S. Securities and Exchange Commission (the ?SEC?) a Form
ID, including amendments thereto, and any other documents necessary or
appropriate to obtain codes and passwords enabling the undersigned to make
electronic filings with the SEC of reports required by Section 16(a) of
the Securities Exchange Act of 1934 and any rule or regulation of the SEC;
(2) execute for and on behalf of the undersigned, in the undersigned?s capacity
as an officer and/or director of Medtronic plc (the ?Company?), Forms 3, 4 and
5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and
the rules thereunder;
(3) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Forms 3, 4, 5,
complete and execute any amendment or amendments thereto, and timely file such
form with the SEC; and
(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it
being understood that the documents executed by such attorney-in-fact on
behalf of the undersigned pursuant to this Power of Attorney shall be in
such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact?s discretion.
The undersigned hereby grants to each attorney-in-fact full power and authority
to do and perform all and every act and thing whatsoever requisite, necessary
and proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact?s substitute or substitutes, shall lawfully do or cause
to be done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned?s responsibilities to
comply with Section 16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, 5 with respect to the
undersigned?s holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact. This Power of Attorney shall
supersede any and all existing Powers of Attorney with respect to the
subject matter hereof.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 28 day of March, 2019.
/s/ Hooman C. Hakami
Hooman C. Hakami